Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Tetracaine HCl (also called Amethocalne; Butylocaine; Curtacain; Decicain; Gingicain; PantocaineM; Intercaine; Leocaine; Menonasal; Niphanoid), the hydrochloride salt form of tetracaine, is a local anaesthetic and a channel function allosteric inhibitor. Tetracaine is used as a local anesthetic to numb the throat, nose, or eyes. It can also be applied topically to reduce pain before beginning an intravenous. Tetracaine works by preventing the sarcoplasmic reticulum's voltage-sensitive Ca2+ release. Additionally, tetracaine inhibits both Na+ CP types IV α and X α.
Targets |
Calcium channel
|
---|---|
ln Vitro |
Tetracaine hydrochloride (Amethocaine hydrochloride) is applied to modify the activity of ryanodine receptors, or calcium release channels, which regulate the release of calcium from intracellular reserves. Tetracaine hydrochloride inhibits channel function allosterically. Tetracaine inhibits spontaneous calcium release events initially at low concentrations and completely blocks release at high concentrations[1][2].
|
References |
[1]. http://en.wikipedia.org/wiki/Tetracaine
[2]. http://www.ncbi.nlm.nih.gov/pubmed/9147318 |
Molecular Formula |
C15H25CLN2O2
|
|
---|---|---|
Molecular Weight |
300.82
|
|
Exact Mass |
300.16
|
|
Elemental Analysis |
C, 59.89; H, 8.38; Cl, 11.78; N, 9.31; O, 10.64
|
|
CAS # |
136-47-0
|
|
Appearance |
Solid powder
|
|
SMILES |
CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl
|
|
InChi Key |
PPWHTZKZQNXVAE-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C15H24N2O2.ClH/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3;/h6-9,16H,4-5,10-12H2,1-3H3;1H
|
|
Chemical Name |
2-(dimethylamino)ethyl 4-(butylamino)benzoate;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3242 mL | 16.6212 mL | 33.2425 mL | |
5 mM | 0.6648 mL | 3.3242 mL | 6.6485 mL | |
10 mM | 0.3324 mL | 1.6621 mL | 3.3242 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02863679 | Completed | Drug: Tetracaine hydrochloride gel |
Hysteroscopy | Wenzhou Medical University | May 2016 | Not Applicable |
NCT01304316 | Completed | Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05% |
Anesthesia | St. Renatus, LLC | September 2010 | Phase 2 |
NCT01710787 | Completed | Drug: Tetracaine HCl 3% Drug: Placebo |
Anesthesia | St. Renatus, LLC | October 2012 | Phase 3 |
NCT01807624 | Completed | Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05% |
Anesthesia | St. Renatus, LLC | March 2013 | Phase 2 |
NCT01952990 | Completed | Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05% |
Anesthesia | St. Renatus, LLC | September 2013 | Phase 2 |